SEC Form 4 · accession 0001203311-17-000070
SEATTLE GENETICS INC /WA · SGEN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Darren S Cline
Officer — EVP, Commercial
Period of report
Aug 31, 2017
Accepted (ET)
Sep 5, 2017 · 7:23 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001060736
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 31, 2017 | M | 2,907 | $18.46 | A | 79,775 | D | |
| Common StockF2,F1 | Aug 31, 2017 | S | 2,907 | $52.5188 | D | 76,868 | D | |
| Common StockF1 | Aug 31, 2017 | S | 4,662 | $52.5084 | D | 72,206 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F3 | $18.46 | Aug 31, 2017 | M | 2,907 | D | — | Feb 28, 2022 | Common Stock | 2,907 | 0 | D |
Explanation of responses
- F1Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.
- F2Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $52.5175 to $52.52. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F3Shares vested at a rate of 25% on 2/29/2013 and monthly thereafter until all the shares were fully vested on 2/29/2016.